This article needs additional citations for verification. (October 2018) (Learn how and when to remove this template message)
Screening, in medicine, is a strategy used in a population to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms. This can include individuals with pre-symptomatic or unrecognized symptomatic disease. As such, screening tests are somewhat unusual in that they are performed on persons apparently in good health.
Screening interventions are designed to identify disease in a community early, thus enabling earlier intervention and management in the hope to reduce mortality and suffering from a disease. Although screening may lead to an earlier diagnosis, not all screening tests have been shown to benefit the person being screened; overdiagnosis, misdiagnosis, and creating a false sense of security are some potential adverse effects of screening. Additionally, some screening tests can be inappropriately overused. For these reasons, a test used in a screening program, especially for a disease with low incidence, must have good sensitivity in addition to acceptable specificity.
Several types of screening exist: universal screening involves screening of all individuals in a certain category (for example, all children of a certain age). Case finding involves screening a smaller group of people based on the presence of risk factors (for example, because a family member has been diagnosed with a hereditary disease). Screening interventions are not designed to be diagnostic, and often have significant rates of both false positive and false negative results.
In 1968, the World Health Organization published guidelines on the Principles and practice of screening for disease, which often referred to as Wilson and Jungner criteria. The principles are still broadly applicable today:
- The condition should be an important health problem.
- There should be a treatment for the condition.
- Facilities for diagnosis and treatment should be available.
- There should be a latent stage of the disease.
- There should be a test or examination for the condition.
- The test should be acceptable to the population.
- The natural history of the disease should be adequately understood.
- There should be an agreed policy on whom to treat.
- The total cost of finding a case should be economically balanced in relation to medical expenditure as a whole.
- Case-finding should be a continuous process, not just a "once and for all" project.
In 2008, with emergence of new genomic technologies, the WHO synthesised and modified these with the new understanding as follows:
Synthesis of emerging screening criteria proposed over the past 40 years
- The screening programme should respond to a recognized need.
- The objectives of screening should be defined at the outset.
- There should be a defined target population.
- There should be scientific evidence of screening programme effectiveness.
- The programme should integrate education, testing, clinical services and programme management.
- There should be quality assurance, with mechanisms to minimize potential risks of screening.
- The programme should ensure informed choice, confidentiality and respect for autonomy.
- The programme should promote equity and access to screening for the entire target population.
- Programme evaluation should be planned from the outset.
- The overall benefits of screening should outweigh the harm.
- Mass screening : Mass screening means, the screening of a whole population or a subgroup. It is offered to all, irrespective of the risk status of the individual.
- High risk or selective screening : High risk screening is conducted among risk populations only.
- Multiphasic screening : It is the application of two or more screening tests to a large population at one time instead of carrying out separate screening tests for single diseases.
- When done thoughtfully and based on research, identification of risk factors can be a strategy for medical screening.
In many countries there are population-based screening programmes. In some countries, such as the UK, these operate at a national level. Common screening programmes include:
- Cancer screening
- PPD test to screen for exposure to tuberculosis
- Beck Depression Inventory to screen for depression
- SPAI-B, the Liebowitz Social Anxiety Scale and Social Phobia Inventory to screen for social anxiety disorder
- Alpha-fetoprotein, blood tests and ultrasound scans for pregnant women to detect fetal abnormalities
- Bitewing radiographs to screen for interproximal dental caries
- Ophthalmoscopy or digital photography and image grading for diabetic retinopathy
- Ultrasound scan for abdominal aortic aneurysm
- Screening of potential sperm bank donors
- Screening for metabolic syndrome
- Screening for potential hearing loss in newborns
Most public school systems in the United States screen students periodically for hearing and vision deficiencies and dental problems. Screening for spinal and posture issues such as scoliosis is sometimes carried out, but is controversial as scoliosis (unlike vision or dental issues) is found in only a very small segment of the general population and because students must remove their shirts for screening. Many states no longer mandate scoliosis screenings, or allow them to be waived with parental notification. There are currently bills being introduced in various U.S. states to mandate mental health screenings for students attending public schools in hopes to prevent self-harm as well as the harming of peers. Those proposing these bills hope to diagnose and treat mental illnesses such as depression and anxiety.
Medical equipment usedEdit
Medical equipment used in screening tests is usually different from equipment used in diagnostic tests as screening tests are used to indicate the likely presence or absence of a disease or condition in people not presenting symptoms; while diagnostic medical equipment is used to make quantitative physiological measurements to confirm and determine the progress of a suspected disease or condition. Medical screening equipment must be capable of fast processing of many cases, but may not need to be as precise as diagnostic equipment.
Screening can detect medical conditions at an early stage before symptoms present while treatment is more effective than for later detection. In the best of cases lives are saved. Like any medical test, the tests used in screening are not perfect. The test result may incorrectly show positive for those without disease (false positive), or negative for people who have the condition (false negative). Limitations of screening programmes can include:
- Screening can involve cost and use of medical resources on a majority of people who do not need treatment.
- Adverse effects of screening procedure (e.g. stress and anxiety, discomfort, radiation exposure, chemical exposure).
- Stress and anxiety caused by prolonging knowledge of an illness without any improvement in outcome. This problem is referred to as overdiagnosis (see also below).
- Stress and anxiety caused by a false positive screening result.
- Unnecessary investigation and treatment of false positive results (namely misdiagnosis with Type I error).
- A false sense of security caused by false negatives, which may delay final diagnosis (namely misdiagnosis with Type II error).
Screening for dementia in the English NHS is controversial because it could cause undue anxiety in patients and support services would be stretched. A GP reported "The main issue really seems to be centred around what the consequences of a such a diagnosis is and what is actually available to help patients."
To many people, screening instinctively seems like an appropriate thing to do, because catching something earlier seems better. However, no screening test is perfect. There will always be the problems with incorrect results and other issues listed above.
Before a screening program is implemented, it should ideally be looked at to ensure that putting it in place would do more good than harm. The best studies for assessing whether a screening test will increase a population's health are rigorous randomized controlled trials.
When studying a screening program using case-control or, more usually, cohort studies, various factors can cause the screening test to appear more successful than it really is. A number of different biases, inherent in the study method, will skew results.
Screening may identify abnormalities that would never cause a problem in a person's lifetime. An example of this is prostate cancer screening; it has been said that "more men die with prostate cancer than of it". Autopsy studies have shown that between 14 and 77% of elderly men who have died of other causes are found to have had prostate cancer.
Aside from issues with unnecessary treatment (prostate cancer treatment is by no means without risk), overdiagnosis makes a study look good at picking up abnormalities, even though they are sometimes harmless.
Overdiagnosis occurs when all of these people with harmless abnormalities are counted as "lives saved" by the screening, rather than as "healthy people needlessly harmed by overdiagnosis". So it might lead to a endless cycle: the greater the overdiagnosis, the more people will think screening is more effective than it is, which can reinforce people to do more screening tests, leading to even more overdiagnosis. Raffle Mackie and Gray call this the popularity paradox of screening: "The greater the harm through overdiagnosis and overtreatment from screening, the more people there are who believe they owe their health, or even their life, to the programme"(p56 Box 3.4) 
The screening for neuroblastoma, the most common malignant solid tumor in children, in Japan is a very good example why a screening program must be evaluated rigorously before its implemented. In 1981, Japan started a program of screening for neuroblastoma by measuring homovanillic acid and vanilmandelic acid in urine samples of six-month-old infants. In 2003, a special committee was organized to evaluate the motivation for the neuroblastoma screening program. In the same year, the committee concluded that there was sufficient evidence that screening method used in the time led to overdiagnosis, but there was no enough evidence that the program reduced neuroblastoma deaths. As such, the committee recommended against screening and the Ministry of Health, Labor and Welfare decided to stop the screening program.
Another example of overdiagnosis happened with thyroid cancer: its incidence tripled in United States between 1975 and 2009, while mortality was constant. In South Korea, the situation was even worse with 15-fold increase in the incidence from 1993 to 2011 (the world's greatest increase of thyroid cancer incidence), while the mortality remained stable. The increase in incidence was associated with the introduction of ultrasonography screening.
The problem of overdiagnosis in cancer screening is that at the time of diagnosis it not possible to differentiate between a harmless lesion and lethal one, unless the patient do not treat and dies from other causes. So almost all patients tend to be treated, leading to what is called overtreatment. As researchers Welch and Black put it, “Overdiagnosis—along with the subsequent unneeded treatment with its attendant risks—is arguably the most important harm associated with early cancer detection.” 
Lead time biasEdit
If screening works, it must diagnose the target disease earlier than it would be without screening (when symptoms appear).
Even if in both cases a person will die at the same time, because we diagnosed the disease earlier with screening the survival time since diagnosis is longer with screening; even in the case life span has not been prolonged, and there will be added anxiety as the patient must live with knowledge of the disease for longer.
If screening works, it must introduce a lead time. So statistics of survival time since diagnosis tends increase with screening because of the lead time introduced, even when screening offers no benefits. If we do not think about what survival time actually means in this context, we might attribute success to a screening test that does nothing but advance diagnosis; comparing statistics of mortality due to a disease in a screened and unscreened population gives more meaningful information.
Length time biasEdit
Many screening tests involve the detection of cancers. Screening is more likely to detect slower-growing tumors (due to longer pre-clinical sojourn time) that are less likely to cause harm. Also, those aggressive cancers tend to produce symptoms in the gap between scheduled screening, being less likely to detected by screening. So, the cases screening often detects automatically have better prognosis than symptomatic cases. The consequence is those more slow progressive cases are now classified as cancers, which increases the incidence, and due to its better prognosis, the survival rates of screened people will be better than non-screening even if screening makes no difference.
Not everyone will partake in a screening program. There are factors that differ between those willing to get tested and those who are not.
If people with a higher risk of a disease are more likely to be screened, for instance women with a family history of breast cancer are more likely than other women to join a mammography program, then a screening test will look worse than it really is: negative outcomes among the screened population will be higher than for a random sample.
Selection bias may also make a test look better than it really is. If a test is more available to young and healthy people (for instance if people have to travel a long distance to get checked) then fewer people in the screening population will have negative outcomes than for a random sample, and the test will seem to make a positive difference.
Studies have shown that people who attend screening tend to be healthier than those who do not. This has been called the healthy screenee effect. The reason seems to be that people who are healthy, affluent, physically fit, non-smokers with long-lived parents are more likely to come and get screened than those on low-income, who have existing health and social problems.
Study Design for the Research of Screening ProgramsEdit
The best way to minimize selection bias is to use a randomized controlled trial, though observational, naturalistic, or retrospective studies can be of some value and are typically easier to conduct. Any study must be sufficiently large (include many patients) and sufficiently long (follow patients for many years) to have the statistical power to assess the true value of a screening program. For rare diseases, hundreds of thousands of patients may be needed to realize the value of screening (find enough treatable disease), and to assess the effect of the screening program on mortality a study may have to follow the cohort for decades. Such studies take a long time and are expensive, but can provide the most useful data with which to evaluate the screening program and practice evidence-based medicine.
All-cause mortality vs disease-specific mortalityEdit
The main outcome of cancer screening studies is usually the number of deaths caused by the disease being screened for - this is called disease-specific mortality. To give an example: in trials of mammography screening for breast cancer, the main outcome reported is often breast cancer mortality. However, disease-specific mortality might be biased in favor of screening. In the example of breast cancer screening, women overdiagnosed with breast cancer might receive radiotherapy, which increases mortality due to lung cancer and heart disease. The problem is those deaths are often classified as other causes and might even be larger than the number of breast cancer deaths avoided by screening. So the non-biased outcome is all-cause mortality. The problem is that much larger trials are needed to detect a significant reduction in all-cause mortality. In 2016, researcher Vinay Prasad and colleagues published an article in BMJ titled "Why cancer screening has never been shown to save lives", as cancer screening trials did not show all-cause mortality reduction.
- O’Sullivan, Jack W; Albasri, Ali; Nicholson, Brian D; Perera, Rafael; Aronson, Jeffrey K; Roberts, Nia; Heneghan, Carl (11 February 2018). "Overtesting and undertesting in primary care: a systematic review and meta-analysis". BMJ Open. 8 (2): e018557. doi:10.1136/bmjopen-2017-018557. PMC 5829845. PMID 29440142.
- O’Sullivan, Jack W.; Heneghan, Carl; Perera, Rafael; Oke, Jason; Aronson, Jeffrey K.; Shine, Brian; Goldacre, Ben (19 March 2018). "Variation in diagnostic test requests and outcomes: a preliminary metric for OpenPathology.net". Scientific Reports. 8 (1): 4752. Bibcode:2018NatSR...8.4752O. doi:10.1038/s41598-018-23263-z. PMC 5859290. PMID 29556075.
- Screening and Diagnostic Tests at eMedicine
- Hall, Harriet (2019). "Too Many Medical Tests". Skeptical Inquirer. 43 (3): 25–27.
- Wilson, JMG; Jungner, G (1968). "Principles and practice of screening for disease" (PDF). WHO Chronicle. 22 (11): 473Public Health Papers, #34.
- Anne Andermann, Ingeborg Blancquaert, Sylvie Beauchamp, Véronique Déry Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years: Bulletin of the World Health Organization; 2008 Volume 86, Number 4, April 2008, 241-320
- Wald, N J; Hackshaw, A K; Frost, C D (1999). "When can a risk factor be used as a worthwhile screening test?". BMJ. 319 (7224): 1562–1565. doi:10.1136/bmj.319.7224.1562. ISSN 0959-8138. PMC 1117271. PMID 10591726.
- "GPs hit by widespread complaints from patients 'unhappy' over dementia screening". Pulse. 22 November 2013. Retrieved 22 November 2013.
- The Complete Book of Men's Health. Men's Health Books. Rodale Books. 2000. ISBN 9781579542986.[page needed]
- Sandhu GS, Adriole GL. Overdiagnosis of prostate cancer. Journal of the National Cancer Institute Monographs 2012 (45): 146–151.
- Brodersen J, Kramer BS, Macdonald H, et al. 2018. Focusing on overdiagnosis as a driver of too much medicine. BMJ 362: k3494. doi: 10.1136/bmj.k3494.
- Raffle AE, Mackie A, Gray JAM. Screening: Evidence and Practice.2nd edition Oxford University Press. 2019
- Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med. 2004 May 6;350(19):2010-1. DOI:10.1056/NEJM200405063501922
- Esserman LJ, Thompsom IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014 May; 15(6): e234–e242. doi: 10.1016/S1470-2045(13)70598-9
- Ahn, H.S.; Kim, H.J.; Welch, H.G. Korea’s thyroid-cancer “epidemic”—Screening and overdiagnosis. N Engl J Med. 2014 371, 1765–176 doi 10.1056/NEJMp1409841
- Ahn HS, Kim HJ, Kim KH. T hyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid, 26(11), 1535–1540. doi:10.1089/thy.2016.0075
- Welch, H. G.; Black, W. C. (2010). "Overdiagnosis in Cancer". JNCI Journal of the National Cancer Institute. 102 (9): 605–613. doi:10.1093/jnci/djq099. PMID 20413742.
- Carter SM, Barratt A. What is overdiagnosis and why should we take it seriously in cancer screening? Public Health Res Pract. 2017;27(3):e2731722. doi: 10.17061/phrp2731722
- Gøtzsche, P.C., Commentary: Screening: A seductive paradigm that has generally failed us., 2015, International Journal of Epidemiology, 244(1): 278-280 DOI, 
- Prasad V., Lenzer J., Newman D.H., Why cancer screening has never been shown to "save lives"--and what we can do about it.British Medical Journal 2016; 352:h6080 DOI
- UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. 2009. Last accessed April 22, 2009.
- Raffle, Angela E.; Mackie, Anne; Muir Gray, J. A. (2019). Screening: Evidence and practice. Oxford University Press. doi:10.1093/acprof:oso/9780199214495.001.0001. ISBN 978-0-19-8805984.
- Health Knowledge Interactive Learning Module on Screening by Angela Raffle. Last accessed January 18, 2010.